BOSTON, August 5, 2025 — Leads & Copy — Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the Phase 2 AMPLIFY-7P study in mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) without modifications, following an interim review of unblinded safety and efficacy data. The IDMC also confirmed the favorable safety profile of ELI-002 7P to date.
The company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy. The final disease-free survival analysis is anticipated to occur in Q4 2025. Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3 study design. The company’s current cash runway extends into Q1 2026, past the anticipated final DFS analysis.
Robert Connelly, CEO of Elicio, expressed encouragement and anticipation for the final DFS analysis. The AMPLIFY-7P trial, involving 144 patients, evaluates ELI-002 7P monotherapy compared to standard of care for improving DFS in PDAC patients post-local therapy. ELI-002 7P is an investigational immunotherapy vaccine targeting seven KRAS mutations.
PDAC is an aggressive cancer with a low survival rate. Elicio Therapeutics is advancing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company’s Amphiphile technology aims to enhance the activation of cancer-specific T cells.
Brian Ritchie, LifeSci Advisors, (212) 915-2578, britchie@lifesciadvisors.com
Source: Elicio Therapeutics, Inc.
